News Center

位置：

Honors Announcement

Group News

Media Reports

Unrelenting R&D Innovation | Shijiazhuang Sihua Pharmaceutical Group’s Low-Calcium Peritoneal Dialysis Solution Becomes the Second in China to Pass Evaluation

Category:

Honors Announcement

发布时间：2023-08-24

【概要描述】 Recently, the low-calcium peritoneal dialysis solution (lactate–G1.5%) (2,000 ml, containing 1.5% glucose) developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and has passed the evaluation of quality and therapeutic equivalence for generic drugs, making it the second domestic pharmaceutical company to receive such approval.

Unrelenting R&D Innovation | Shijiazhuang Sihua Pharmaceutical Group’s Low-Calcium Peritoneal Dialysis Solution Becomes the Second in China to Pass Evaluation

Recently, the low-calcium peritoneal dialysis solution (lactate–G1.5%) (2,000 ml, containing 1.5% glucose) developed by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and has passed the evaluation of quality and therapeutic equivalence for generic drugs, making it the second domestic pharmaceutical company to receive such approval.

It is reported that low-calcium peritoneal dialysis solution is primarily used in patients with chronic renal failure who, despite ineffective non-dialytic therapy, require continuous ambulatory peritoneal dialysis.

The successful evaluation of this low-calcium peritoneal dialysis solution further expands the Group’s portfolio of peritoneal dialysis products, creating greater opportunities to meet diversified market demands and further leverage our competitive advantages. To date, the Group has achieved consistency or deemed-consistency evaluation for a total of 55 product varieties encompassing 73 specifications, thereby providing strong support for the company’s advancement up the value chain toward the mid- to high-end segments.

Keywords:

Frequent Breakthroughs in R&D and Innovation | Shijiazhuang Sihua Pharmaceutical Group’s Low-Calcium Peritoneal Dialysis Solution (Lactate–G2.5%) (2,000 ml, containing 2.5% glucose) Becomes the Second in China to Pass Evaluation

Sijituo Alcohol API Approved by Shijiazhuang Sihua Pharmaceutical Group